These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 21570610)
1. Third-line chemotherapy and novel agents for metastatic germ cell tumors. Veenstra CM; Vaughn DJ Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610 [TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments. Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452 [TBL] [Abstract][Full Text] [Related]
3. Current chemotherapeutic approaches for recurrent or refractory germ cell tumors. O'Carrigan B; Grimison P Urol Oncol; 2015 Aug; 33(8):343-54. PubMed ID: 25308563 [TBL] [Abstract][Full Text] [Related]
4. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. Oing C; Lorch A Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143 [TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340 [TBL] [Abstract][Full Text] [Related]
6. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours. Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540 [TBL] [Abstract][Full Text] [Related]
8. Targeted treatment approaches in refractory germ cell tumors. Galvez-Carvajal L; Sanchez-Muñoz A; Ribelles N; Saez M; Baena J; Ruiz S; Ithurbisquy C; Alba E Crit Rev Oncol Hematol; 2019 Nov; 143():130-138. PubMed ID: 31634730 [TBL] [Abstract][Full Text] [Related]
9. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours. Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610 [TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649 [TBL] [Abstract][Full Text] [Related]
11. Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. Miller RE; Markt SC; O'Donnell E; Bernard B; Albiges LK; Beard C; Sweeney CJ Eur Urol Focus; 2017 Dec; 3(6):621-628. PubMed ID: 28753801 [TBL] [Abstract][Full Text] [Related]
12. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025 [TBL] [Abstract][Full Text] [Related]
13. Poor-prognosis germ cell tumors: we have not yet crossed the finish line. Vaughn DJ; Stadtmauer EA J Clin Oncol; 2007 Jan; 25(3):239-40. PubMed ID: 17235039 [No Abstract] [Full Text] [Related]
14. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours. Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898 [TBL] [Abstract][Full Text] [Related]
15. Intensive and timely chemotherapy, the key of success in testicular cancer. Fléchon A; Culine S; Droz JP Crit Rev Oncol Hematol; 2001 Jan; 37(1):35-46. PubMed ID: 11164717 [TBL] [Abstract][Full Text] [Related]
17. Late relapse of germ cell tumors. Oldenburg J; Lorch A; Fosså SD Hematol Oncol Clin North Am; 2011 Jun; 25(3):615-26, x. PubMed ID: 21570613 [TBL] [Abstract][Full Text] [Related]
18. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy. Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194 [TBL] [Abstract][Full Text] [Related]
19. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Kollmannsberger C; Nichols C; Bokemeyer C Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389 [TBL] [Abstract][Full Text] [Related]
20. Paclitaxel, ifosfamide and cisplatin (TIP) beyond its original indication for salvage treatment of germ cell tumors. Voss MH; Feldman DR Onkologie; 2011; 34(8-9):410-1. PubMed ID: 21934338 [No Abstract] [Full Text] [Related] [Next] [New Search]